Quantcast

Latest Idenix Pharmaceuticals Inc. Stories

2010-09-07 06:00:00

CAMBRIDGE, Mass., Sept. 7 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold. A clinical hold is an order issued by the FDA to the sponsor to delay...

2010-07-26 15:05:00

CAMBRIDGE, Mass., July 26 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million. Research and Development Highlights Phase IIa: IDX184, a liver-targeted hepatitis C virus (HCV)...

2010-07-19 15:05:00

CAMBRIDGE, Mass., July 19 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the second quarter of 2010 on Monday, July 26, 2010 after U.S. financial markets close. Idenix management will host a conference call at 4:30 p.m. ET on Monday, July 26, 2010 to discuss the company's financial results for the second quarter of 2010 and provide an update on the company's development programs. To access the call...

2010-06-16 15:05:00

CAMBRIDGE, Mass., June 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the 2010 Wells Fargo Securities Healthcare Conference on Wednesday, June 23, 2010 at 8:00 a.m. ET at the InterContinental hotel, Boston. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in approximately 5-10...

2010-06-10 07:00:00

CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype...

2010-05-10 15:05:00

CAMBRIDGE, Mass., May 10 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the Rodman & Renshaw 6th Annual Global Healthcare Conference on Monday, May 17, 2010 at 11:55 a.m. BST at the Grosvenor House Hotel, London, England. The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com. Please log in...

2010-05-03 15:05:00

CAMBRIDGE, Mass., May 3 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2010. At March 31, 2010, Idenix's cash, cash equivalents and marketable securities totaled $33.8 million. Research and Development Highlights Phase IIa: IDX184, a liver-targeted hepatitis C virus...

2010-04-29 07:09:00

CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 6,460,672 shares of its common stock at a price of $4.35 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately...

2010-04-22 15:05:00

CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc., (Nasdaq: IDIX) announced today that it will report its financial results for the first quarter of 2010 on Monday, May 3, 2010 after U.S. financial markets close. Idenix management will host a conference call at 4:30 p.m. ET on Monday, May 3, 2010 to discuss the company's financial results for the first quarter of 2010 and provide an update on the company's development programs. To access the call please...

2010-04-16 01:00:00

CAMBRIDGE, Mass., April 16 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported promising in vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and selective antiviral activity in multiple genotypes, or strains, of the virus. The favorable pharmacokinetic profile defined in preclinical studies was confirmed by...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related